Andrea Crotti

Andrea Crotti has over 18 years of experience in the pharmaceutical and biotechnology industry. From 2003-2008, they were a PhD Student at Università Vita-Salute San Raffaele Milano, where they studied viral and host factors controlling HIV replication. Andrea then moved to UC San Diego as a Visiting Post-Doc Scholar from 2008-2009 and as an Assistant Research Scientist from 2009-2014. During this time, they worked on understanding mechanisms involved in the positive or negative regulation of transcription in the context of inflammation and neurodegenerative disease. From 2014-2015, they were a Consultant at EMMG Consulting. Andrea then joined Biogen as a Scientist II from 2015-2019, where they led one Drug Discovery Program aimed to target Tau in collaboration with C4 Tx and led to Go/NoGo decisions for two Drug Discovery Programs to treat AD (ASO and mAb). Andrea then joined Astellas Pharma US as a Principal Scientist from 2019-2020, and was involved in Angelman Syndrome Biomarkers and Outcome Measures Team, proposed and developed three novel Drug Discovery Programs (ASD, AS, Ocular MS), contributed to the Strategy Development for CNS-Diseases Portfolio, and managed contracting and interactions with pre-clinical CROs. Andrea then joined Takeda as a Principal Scientist from 2020-2021, and was involved in organizing and leading Monthly Scientific Update meetings, evaluating Business Development Proposals and Due-diligence, and presenting at EMBL-EBI Industry Workshop “Functional Genomics For Neuroscience” and Keystone Symposia “Brain Therapeutics: Disruptive Technologies and Opportunities”. Andrea Crotti is currently an Associate Director at Arrakis Therapeutics.

Andrea Crotti received their Maturita' Scientifica from Liceo Scientifico "G. Peano" in 1996. Andrea then attended Università degli Studi di Milano and obtained their Master's degree in Biotechnology - Pharmaceutic in 2002. Andrea continued their studies at Libera Università Vita-Salute San Raffaele and obtained their Doctor of Philosophy - PhD in Cell/Cellular and Molecular Biology in 2007. In 2016, they earned a Certificate of Completion in High Performance Team Leadership and Management from Forum. In 2019, they obtained a MIT xPRO Drug and Medical Device Development: A Strategic Approach from MIT xPRO.